← Who reports today · Health Care
ZBH · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 4.8% y/y to $2.18B, operating margin 15.0% vs 14.4%, net income $198M (+29.8% y/y).
Net Earnings of Zimmer Biomet Holdings, Inc.
$198M
up 29.8% y/y
Net Sales
$2,177M
up 4.8% y/y
Operating Profit
$326M
up 8.7% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net Sales | $2,177 · +4.8% |
| Cost of products sold, excluding intangible asset amortization | $636 · +7.3% |
| Intangible asset amortization | $163 · +1.7% |
| Research and development | $105 · −7.5% |
| Selling, general and administrative | $899 · +10.4% |
| Restructuring and other cost reduction initiatives | $29.8 · +70.3% |
| Acquisition, integration, divestiture and related | $18.1 · −77.1% |
| Operating Profit | $326 · +8.7% · 15.0% margin |
| Other income, net | $1.9 · −51.3% |
| Interest expense, net | $72.9 · −8.1% |
| Earnings before income taxes | $255 · +13.6% |
| Provision for income taxes | $55.5 · −22.1% · 21.8% effective rate |
| Less: Net earnings attributable to noncontrolling interest | $1.3 · +117% |
| Net Earnings of Zimmer Biomet Holdings, Inc. | $198 · +29.8% · $1.03/sh · 9.1% margin |
Verdict: revenue grew 4.8% y/y to $2.18B, operating margin 15.0% vs 14.4%, net income $198M (+29.8% y/y).
Operating cash flow was $447.9 million and free cash flow was $308.3 million.
Source and notation
Source: Zimmer Biomet press release, 8-K EX-99.1 of 08/05/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: ZBH, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “ZBH Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/zbh/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/zbh/q2-2026"><img src="https://whoreportstoday.com/t/zbh/q2-2026/sankey.png" alt="ZBH Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/zbh/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/zbh/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/zbh/q2-2026">ZBH Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Net sales rose 4.8% as reported and 4.0% on an organic constant currency basis.
- Operating income was $326M, a 15.0% margin vs 14.4% a year earlier.
- The effective tax rate was 21.8% vs 31.7% a year earlier.
- Diluted EPS was $1.03 vs $0.77 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
ZBH — a medical technology company that designs, makes and sells products for treating bones, joints and soft tissue: knee and hip implants, sports medicine, extremities and trauma devices, craniomaxillofacial and thoracic products, bone cement and surgical products, plus robotic and digital surgery tools for surgeons and hospitals.
It reports three regional segments: Americas (the largest), EMEA and Asia Pacific. · Source: annual report (Form 10-K, SEC)
More reports: ZTS · Q2 2026 · A · Q3 FY2026 · ABBV · Q3 2026 · ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · BDX · Q3 FY2026 · BIIB · Q3 2026 · BMY · Q3 2026 · all reports